The Cyberspace Administration clarifies its approach to the export of personal and important information out of China; UK weighs whether to include China in foreign influence disclosure rules; and Burberry wins online trademark infringement suit.
Partner Xiangxiang Ma of Anjie Broad Law Firm examines the advantages and disadvantages of two key approaches to the legal protection of vital AI algorithms
China to block Chinese firms from investing in the U.S. amid tariff war; Shenzhen launches incentives for foreign-owned hospitals following national legislation; and U.S. companies plan continuous engagement with China
Cybersecurity Law amendment draft imposes heavier penalties. China proposes different data protection periods for three categories of drugs. Facial information collection requires obligations of informing individuals.
State Council restricts provision of evidence outside of mainland China for IP cases / CLP Reference: 5100/25.03.13 ; Promulgated: 2025-03-13 ; Effective: 2025-05-01
Total asset requirement is relaxed for Hong Kong and Macao insurance company investments / CLP Reference: 3910/25.02.26 ; Issued: 2025-02-26 ; Effective: 2025-03-01
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
Jianwei (Jerry) Fang, Xiaoyu (Arthur) Jin and Haoyi Sun of Zhong Lun Law Firm discuss the reasons behind, and the implications of, Illumina’s inclusion in China’s Unreliable Entity List, as well as compliance recommendations for multinational corporations
China strengthens Anti-Foreign Sanctions Law in response to U.S. restrictions; Chinese firms move production facilities overseas amidst key economic changes; and China introduces regulations to protect interests in overseas IP disputes